INSMInsmed
About Insmed
Insmed (NASDAQ:INSM) is a biopharmaceutical company focused on developing and commercializing treatments for serious and rare diseases. Its operations are primarily rooted in research, aiming to address unmet medical needs in respiratory and infectious diseases. Among its key projects is the work on ARIKAYCE®, a treatment designed to fight against nontuberculous mycobacterial (NTM) lung disease for patients who have limited or no treatment options. Insmed's objectives revolve around delivering innovative therapies that can significantly improve patients' lives while expanding their pipeline through strategic development and commercialization efforts. The company's approach includes a blend of in-house research and potential partnerships or acquisitions to bolster its product offerings.
What is INSM known for?
Snapshot
Public US
Ownership
1988
Year founded
923
Employees
New Jersey, United States
Head office
1 of 4
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
United States
Products and/or services of Insmed
- ARIKAYCE®, the first and only FDA-approved treatment for MAC lung disease in adults who have limited or no alternative treatment options.
- Amikacin Liposome Inhalation Suspension, designed to deliver medication directly to the site of infection for patients with nontuberculous mycobacterial (NTM) lung disease.
- Brensocatib, an investigational oral drug for the treatment of bronchiectasis and other inflammatory diseases by inhibiting DPP1, a key enzyme in neutrophil activation.
- TPIP, an inhaled therapy under development aimed at treating refractory nontuberculous mycobacterial lung disease by delivering antimicrobials directly to the lungs.
- ALIS (Amikacin Liposome Inhalation Suspension) in development for patients with cystic fibrosis to target chronic pseudomonas aeruginosa lung infections.
- An ongoing commitment to research and development focused on rare diseases, with a pipeline designed to address unmet medical needs in respiratory and infectious diseases.
Insmed executive team
- Mr. William H. Lewis J.D., M.B.A.President, CEO & Chairman
- Ms. Sara M. Bonstein M.B.A.Chief Financial Officer
- Mr. Roger Adsett M.B.A.Chief Operating Officer
- Dr. Martina Flammer M.B.A., M.D.Chief Medical Officer
- Mr. Brian K. Kaspar Ph.D.Chief Scientific Officer
- Bryan DunnVice President of Investor Relations
- Mr. Michael Alexander Smith J.D.Chief Legal Officer & Corporate Secretary
- Ms. Christie CamelioChief Compliance Officer
- Ms. Claire MulhearnVice President of Corporate Communications
- Ms. S. Nicole Schaeffer M.B.A.Chief People Strategy Officer